Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Heather Wakelee is an Oncologist in Palo Alto, California. Wakelee has been practicing medicine for over 27 years and is rated as an Elite expert by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. She is also highly rated in 17 other conditions, according to our data. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Hormone Replacement Therapy (HRT), and Tissue Biopsy. Wakelee is currently accepting new patients.
Abraham Chachoua is a Hematologist Oncology specialist and a Hematologist in Brooklyn, New York. Chachoua has been practicing medicine for over 44 years and is rated as a Distinguished expert by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. He is also highly rated in 30 other conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Lung Adenocarcinoma. Chachoua is currently accepting new patients.
Christopher Azzoli is a Hematologist Oncology specialist and an Oncologist in Providence, Rhode Island. Azzoli has been practicing medicine for over 27 years and is rated as a Distinguished expert by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. He is also highly rated in 12 other conditions, according to our data. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer. Azzoli is currently accepting new patients.
Summary: The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the anaplastic lymphoma kinase (ALK) gene. Other study aims are to learn about the progression of NSCLC and participants' response to treatment with brigatinib.
Summary: The primary purpose of this study is to evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.